

Mark B Efron

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9120508/mark-b-effron-publications-by-year.pdf>

Version: 2024-04-16

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

3,900
citations

32
h-index

61
g-index

112
ext. papers

4,352
ext. citations

6.7
avg, IF

4.47
L-index

#	Paper	IF	Citations
85	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 1981-1990	59.2	37
84	Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. <i>JAMA Cardiology</i> , 2020 , 5, 598-607	16.2	29
83	Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. <i>Clinical Research in Cardiology</i> , 2020 , 109, 725-734	6.1	4
82	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 95, 885-892	2.7	3
81	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 94, 53-60	2.7	1
80	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, E112-E119	2.7	6
79	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2019 , 275, 31-35	3.2	10
78	Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, E204-E210	2.7	10 ⁴
77	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study. <i>Journal of the American Heart Association</i> , 2018 , 7, e01077	6	2
76	Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy - "Real World" Experience. <i>Progress in Cardiovascular Diseases</i> , 2018 , 60, 531-536	8.5	5
75	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 319-329	3.8	13
74	The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 91, 242-250	2.7	1
73	One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database. <i>American Journal of Cardiovascular Drugs</i> , 2018 , 18, 129-141	4	4
72	Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 629-637	2.7	45
71	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017 , 188, 73-81	4.9	20
70	Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study. <i>JAMA Cardiology</i> , 2017 , 2, 750-757	16.2	39
69	Association of measured platelet reactivity with changes in P2Y receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. <i>American Heart Journal</i> , 2017 , 187, 19-26	4.9	11

68	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 2017-2025	5	27
67	Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10, 10-19	4.9	47
66	Multivessel Versus Culprit Vessel-Only Percutaneous Coronary Intervention Among Patients With Acute Myocardial Infarction: Insights From the TRANSLATE-ACS Observational Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	9
65	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of	6	15
64	Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Circulation</i> , 2016 , 133, 493-501	16.7	19
63	Impact of Bleeding on Quality of Life in Patients on DAPT: Insights From TRANSLATE-ACS. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 59-65	15.1	32
62	How Reliable are Patient-Reported Rehospitalizations? Implications for the Design of Future Practical Clinical Studies. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	10
61	Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016 , 9,	6	10
60	Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 395-403	2.2	1
59	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	8
58	"Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 88, 535-544	2.7	47
57	Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 201-210	6	10
56	One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel. <i>American Journal of Cardiovascular Drugs</i> , 2015 , 15, 337-50	4	17
55	Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor. <i>Journal of Medical Economics</i> , 2015 , 18, 898-908	2.4	9
54	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. <i>American Heart Journal</i> , 2015 , 170, 706-14	4.9	4
53	Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Circulation</i> , 2015 , 132, 174-81	16.7	38
52	Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 347-56	5.8	44
51	Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1880-9	5	70

50	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 499-508	4.3	59
49	Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1500-9	15.1	78
48	Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. <i>Current Medical Research and Opinion</i> , 2014 , 30, 2207-16	2.5	21
47	Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1700-2	15.1	9
46	Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 311-22	7	7
45	Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention. <i>American Journal of Cardiovascular Drugs</i> , 2013 , 13, 263-71	4	20
44	Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 6, 567-74	6	39
43	Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1223-31	7	12
42	Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 347-55	7	16
41	Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. <i>American Heart Journal</i> , 2011 , 162, 844-51	4.9	47
40	A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes Mellitus (OPTIMUS)-3 Trial. <i>European Heart Journal</i> , 2011 , 32, 838-46	9.5	161
39	The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data. <i>Journal of Cardiovascular Pharmacology</i> , 2011 , 57, 317-24	3.1	11
38	Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1017-23	15.1	148
37	Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INTERvention with Enhanced Reperfusion Speed to Stop Events). <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 203-12	5	32
36	A prospective, observational study of Xigris Use in the United States (XEUS). <i>Journal of Critical Care</i> , 2010 , 25, 660.e9-16	4	2
35	Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. <i>Circulation</i> , 2009 , 119, 922-30	16.7	89
34	Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 917-24	5	66
33	1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 909-16	5	48

32	Antibiotic overuse: the influence of social norms. <i>Journal of the American College of Surgeons</i> , 2008 , 207, 265-75	4.4	50
31	Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). <i>Stroke</i> , 2008 , 39, 87-99	6.7	305
30	Facilitated PCI in patients with ST-elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2008 , 358, 2205-17	59.2	497
29	Treating patients with wake-up stroke: the experience of the AbESTT-II trial. <i>Stroke</i> , 2008 , 39, 3277-82	6.7	53
28	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 459-68	3.8	19
27	Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 96, 474-81	3	61
26	Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2004 , 61, 2664-71	2.2	4
25	Final results of the ReoPro readministration registry. <i>American Journal of Cardiology</i> , 2004 , 93, 979-84	3	39
24	Safety Of Drotrecogin Alfa (Activated): Results Of XEUS, A Prospective Multicenter Observational Study. <i>Chest</i> , 2004 , 126, 724S	5.3	2
23	Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. <i>Circulation</i> , 2003 , 108, 1316-23	16.7	120
22	Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). <i>American Journal of Cardiology</i> , 2003 , 92, 779-84	3	12
21	A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16 Suppl 1, S33-61	3.9	28
20	Abciximab readministration: results of the ReoPro Readministration Registry. <i>Circulation</i> , 2001 , 104, 870-5	16.7	127
19	Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. <i>Circulation</i> , 2000 , 101, 1122-9	16.7	40
18	Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. <i>American Heart Journal</i> , 2000 , 140, 492-501	4.9	16
17	Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. <i>Annals of Thoracic Surgery</i> , 2000 , 70, 516-26	2.7	70
16	Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. <i>Drugs and Aging</i> , 2000 , 16, 179-87	4.7	16
15	Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. <i>American Journal of Cardiology</i> , 1999 , 84, 728-30, A8	3	25

14	Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study. <i>Catheterization and Cardiovascular Interventions</i> , 1999 , 48, 430-4	2.7	10
13	Readministration of abciximab: interim report of the ReoPro readministration registry. <i>American Heart Journal</i> , 1999 , 138, S33-8	4.9	24
12	Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. <i>Circulation</i> , 1998 , 98, 734-41	16.7	570
11	Abciximab Reduces Urgent Target Vessel Revascularization at 30 Days After Primary Angioplasty, Independently of Acute Angiographic Results. The RAPPORT Trial. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 54A	15.1	5
10	Safety of Readministration of Abciximab; Interim Results of the ReoPro Readministration Registry (R3). <i>Journal of the American College of Cardiology</i> , 1998 , 31, 55A	15.1	5
9	Abciximab Reduces the Need for Bail-out Stenting During Primary Angioplasty. The RAPPORT Trial. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 237A	15.1	3
8	Synergy of Abciximab and Ticlopidine in Patients Undergoing Intracoronary Stenting. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 238A	15.1	2
7	Effects of integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. <i>Circulation</i> , 1996 , 94, 2083-9	16.7	74
6	Hemodynamic vascular forces contribute to impaired endothelium-dependent vasodilation in reperfused canine epicardial coronary arteries. <i>Journal of the American College of Cardiology</i> , 1994 , 23, 1216-23	15.1	1
5	False positive signal-averaged ECG produced by junctional rhythm with retrograde P waves. <i>American Heart Journal</i> , 1992 , 123, 1701-3	4.9	2
4	Effects of resistive training on left ventricular function. <i>Medicine and Science in Sports and Exercise</i> , 1989 , 21, 694-7	1.2	28
3	Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm. <i>American Journal of Cardiology</i> , 1988 , 62, 1202-7	3	104
2	Elastic properties of the human chest during cardiopulmonary resuscitation. <i>Critical Care Medicine</i> , 1983 , 11, 685-92	1.4	52
1	Two-dimensional echocardiographic features diagnostic of isolated pulmonic valve endocarditis. <i>American Heart Journal</i> , 1982 , 103, 137-9	4.9	10